Research ArticleRheumatoid Arthritis
Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs
Fenglong Xie, Lang Chen, Huifeng Yun, Emily B. Levitan and Jeffrey R. Curtis
The Journal of Rheumatology June 2021, 48 (6) 804-812; DOI: https://doi.org/10.3899/jrheum.191326
Fenglong Xie
1F. Xie, PhD, H. Yun, PhD, J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, and Department of Epidemiology, University of Alabama at Birmingham;
Lang Chen
2L. Chen, PhD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham;
Huifeng Yun
1F. Xie, PhD, H. Yun, PhD, J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, and Department of Epidemiology, University of Alabama at Birmingham;
Emily B. Levitan
3E.B. Levitan, ScD, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Jeffrey R. Curtis
1F. Xie, PhD, H. Yun, PhD, J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, and Department of Epidemiology, University of Alabama at Birmingham;
In this issue
The Journal of Rheumatology
Vol. 48, Issue 6
1 Jun 2021
Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs
Fenglong Xie, Lang Chen, Huifeng Yun, Emily B. Levitan, Jeffrey R. Curtis
The Journal of Rheumatology Jun 2021, 48 (6) 804-812; DOI: 10.3899/jrheum.191326
Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs
Fenglong Xie, Lang Chen, Huifeng Yun, Emily B. Levitan, Jeffrey R. Curtis
The Journal of Rheumatology Jun 2021, 48 (6) 804-812; DOI: 10.3899/jrheum.191326